Polycomb group (Pc-G) proteins associate to form large complexes that repress Hox genes, thereby imposing Hox gene expression pattern required for development. However, Pc-G proteins have a Hox-independent function in controlling cell proliferation. Here we show that embryonic fibroblasts derived from M33-deficient mice are impaired in the progression into the S phase of the cell cycle, as shown by a reduced rate of incorporation of bromodeoxyuridine. These cells have a senescent phenotype, associated to an abnormal accumulation of the cyclin-dependent kinase inhibitor p16INK4a protein.
Introduction
Pc-G and Trx-G proteins form an evolutionary conserved cellular memory system that enables stable transmission of gene activity throughout cell division (Pirrotta, 1995) . These proteins were first described in Drosophila as repressors and maintenance activators of homeotic genes (Pirrotta, 1995) . Mutations in Pc-G genes result in homeotic transformations due to ectopic expression of the homeotic genes both in mammals and Drosophila (Gould, 1997) .
Studies of Pc-G mutant mice demonstrated that some of Pc-G genes are essential for hematopoietic cell proliferation and differentiation. Mice lacking the bmi-1 or mel-18 functions present severe lymphopenia, resulting in an impaired proliferative response of precursors cells to cytokine stimulation such as IL-7. Alternatively, the overexpression of mel-18 induces cell cycle arrest in B cells upon B-cell receptor (BCR) stimulation accompanied by a downregulation of c-myc expression, demonstrating that mel-18 negatively regulates cell cycle through a c-myc/cdc25 cascade (Tetsu et al., 1998) . These data suggest that mel-18 may positively or negatively control lymphocytes proliferation triggered by different signal transduction pathways. In contrast, overexpressing bmi-1 causes enhanced proliferation of pro-T and pro-B cells and predispose mice to lymphomagenesis in collaboration with c-myc (Alkema et al., 1997b) . Recently, it has been shown that the Ink4a/Arf tumor suppressor locus is an essential downstream target of bmi-1 repression (Jacobs et al., 1999a) . Proliferation defects and increased apoptosis in lymphoid cells as well as in embryonic fibroblasts (MEF) from bmi-1À/À mice can be reversed by inactivation of the Ink4a/Arf locus (Jacobs et al., 1999a) . The existence of mammalian Polycomb complexes has been biochemically demonstrated, raising the possibility that Pc-G products act, as in Drosophila, in multimeric complexes to achieve their silencing function (Alkema et al., 1997a, c) . Genetic interaction between eed and bmi-1 has demonstrated that hematopoietic cell proliferation is probably regulated by antagonistic functions of repressive and enhancing Pc-G complexes, respectively, containing EED and BMI-1 (Lessard et al., 1999) . Moreover, hyperproliferation of bone marrow progenitors from eed hypomorphe mutant is not accompanied by deregulation of Hox genes and INK4a locus, suggesting that different Pc-G complexes may control different sets of downstream targets. More recently, it has been reported that Pc-G genes such as rae28 and bmi-1 play a crucial role in the regulation of hematopoietic stem cell (HSC) self-renewal and proliferation, but are dispensable for their generation (Ohta et al., 2002; Park et al., 2003) . It is suggested that bmi-1 targets p16INK4a to allow the proliferation of HSCs and p19ARF to inhibit apoptosis through p53.
It has been genetically demonstrated in mouse that the Pc-G products BMI-1 and M33 act in synergy to control the nested expression pattern of specific Hox genes in somitic mesodermal tissues during normal development (Bel et al., 1998) . The synergistic interactions between bmi-1 and M33 mutants during embryonic development indicate their commitment in similar molecular processes and could indicate interactions of the respective gene products in a larger protein complex. This raises the possibility that M33 could exert its effects both on lymphoid cell development (Core´et al., 1997) and on cell cycle control through the regulation of the Ink4a/Arf locus (Jacobs et al., 1999a) . It has been shown that pRB, a critical regulator of the cell cycle, associates with Pc-G proteins RING1 and HPC2, linking the pRB and the Polycomb pathways (Dahiya et al., 2001; erratum 2003) . However, the function of M33 in controlling cell cycle was not yet addressed.
In this paper, we present evidences that M33 negatively controls the Ink4a/Arf locus in lymphoid cells and in MEFs and that the altered proliferative potential of M33À/À MEFs is bypassed by the pRB target E2F when expressed as a dominant-negative form of the E2F/pRB complex repressor activity (Zhang et al., 1999) . These results establish a function of the Polycomb protein M33 in controlling the cell cycle progression through the p19ARF and/or the p16/pRB pathways in an E2F-dependent manner.
Results

Cell cycle progression is impaired in M33À/À MEFs
We showed previously that primary fibroblasts (MEFs) derived from M33À/À embryos were strongly impaired in their ability to expand (Core´et al., 1997) . Although the growth rate of M33-null MEFs was identical to control cells in early passage cultures, mutant cultures notably slowed down as soon as passage P-3. In order to characterize further this abnormal proliferation rate, we analysed the progression of the cell cycle in these mutant cells by incorporation of BrdU and propidium iodide by FACS. Asynchronously passage 5 (P-5) growing cultures of wild-type and M33À/À MEFs were pulselabeled with BrdU for 4 h, then fixed and stained with antibody to BrdU. Data presented in Figure 1 show a reduced proportion of BrdU-positive cells in M33À/À cultures (Figure 1a ), indicating that MEFs fail to progress at a normal rate through the replicating S phase. Similar results were obtained with MEFs synchronized for 24 h in 0.5% serum-supplemented medium prior to BrdU labeling (data not shown). BrdU incorporation combined to DNA content analysis revealed that M33À/À MEFs accumulate in G1 and G2/M phases (Figure 1b) , suggesting that the cells enter a slower rate of division.
M33À/À MEFs prematurely enter senescence
After a limited number of divisions, cells stop to proliferate and undergo a process of replicative senescence. One possibility to explain the abnormal growth phenotype of M33À/À cells is that the mutant cells prematurely achieve their proliferative potential. Senescent cells can be distinguished from quiescent cells by monitoring the endogenous b-galactosidase (b-gal) activity at pH 6. X-gal staining of P-5 MEFs cultures revealed an enhanced activity of senescence-associated b-gal in M33À/À cultures (Figure 2a) . Less than 20% of control cells were positive for b-gal activity, whereas mutant cultures exhibited 80-90% of positive cells. In all, 30 mg of total proteins extracted from subconfluent MEF cultures was fractionated on 10% SDS-acrylamide gel and analysed by immunoblotting using antibodies directed to the indicated proteins. p16INK4a expression from P-2 to P-5 cultures was assayed from wild type (lanes 1, 3, 5, 7) and M33À/À (lanes 2, 4, 6, 8) MEFs. Actin serves as control. (c) Semiquantitative RT-PCR was realized to analyse the expression level of p16INK4a and p19ARF in thymocytes and splenocytes from wild-type and M33À/À mice. For PCR reaction, the first-strand cDNA was diluted as indicated above the lanes. Primers specific for b-actin were used as quantitative control
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Inhibitors of cyclin-dependent kinases (CKIs) of the INK4 and the Cip/Kip families such as p16INK4a, p19ARF and p21Cip are molecular keys of the senescence process. These proteins are known to accumulate in aging cells (Kamijo et al., 1997; Zindy et al., 1997) . Examination of these cell cycle inhibitors in P-5 MEFs by immunoblotting revealed that M33À/À MEFs contain high level of the p16INK4a product compared to controls, whereas expression of p19ARF is slightly increased and P21Cip is unaffected (Figure 2b ). The upregulation of p16INK4a began at P-3, and this abnormal accumulation was enhanced with successive passages (Figure 2b ).
E2F-DB bypasses the proliferative defect of M33-deficient MEFs
It has been demonstrated that E2F-DB mutant protein prevents INK4a-mediated growth arrest and allows cells to proliferate at a normal rate even with a high level of the P16INK4a inhibitor (Zhang et al., 1999) . In addition, recent data show that E2F-DB can rescue cell cycle arrest induced by ectopic p19ARF expression in MEFs (Rowland et al., 2002) . We took advantage of the constitutively positive function of E2F-DB on cell cycle progression to assess if the senescent phenotype of M33-deficient cells depends exclusively on the deregulation of these two signaling pathways. Upon retroviral expression in primary embryonic fibroblasts from passage P-2 cultures, E2F-DB was able to rescue the proliferative potential of M33-null MEFs to a normal rate, whereas mutant MEFs infected by empty retroviral vector failed to proliferate (Figure 3a ). BrdU incorporation assay indicated that the E2F-DB infected M33-null MEFs enter the S phase as well as control cells (Figure 3b ). Western blot analysis at late passage (P-8) revealed that E2F-DB triggered cellular proliferation in spite of P16INK4a and p19ARF accumulation, in agreement with other published data (Zhang et al., 1999) . We also observe an upregulation of p19ARF in mutant and control MEFs expressing ectopic E2F-DB. An E2F-DBdependent upregulation of p19ARF has already been described in primary fibroblasts (Rowland et al., 2002) , indicating that normal E2F protein represses the p19ARF locus. Nevertheless, in spite of p19ARF accumulation, E2F-DB-expressing mutant cells failed to undergo senescence.
Our results show that ectopic E2F-DB bypasses the proliferative defect of M33À/À MEFs, suggesting that the senescent phenotype of the mutant cells could be due to a specific deregulation of the p16INK4 signaling pathway in MEFs.
Developmental impaired expansion in M33À/À lymphoid cells
In a previous work, we described that deletion at the M33 locus leads to a dramatic decrease of lymphoid cell number in the thymus and the spleen in 3-week-old animals. Expression studies revealed that the M33 gene is expressed at all stages of thymocyte maturation (data not shown). In addition, we showed that thymic maturation can progress in M33À/À mutants, but that the double-positive (DP) CD4 þ CD8 þ population from premature precursors is greatly affected (Core et al., 1997) . Moreover, from thymic organo-culture assays, we demonstrated that fetal precursors derived from 12.5 days post coı¨tum (dpc) M33À/À livers failed to expand properly, whereas they were able to differentiate in mature T cells. These preliminary results suggested that mutant lymphoid cells failed to expand both in vitro and in vivo.
We have now extended this analysis in the thymus, spleen and in bone marrow during development of the M33 mutant mice. Figure 4a shows that thymocytes, splenocytes and bone marrow cell numbers are strongly decreased in 3-week-old M33À/À mice, suggesting that the M33 deficiency affects both the B-lymphoid and the T-lymphoid lineages. Since thymocyte maturation starts early during mouse development, we examined the number of lymphoid cells during thymic development starting from 15 dpc embryos to 8-week-old M33 mutant mice (Figure 4b ). Using the CD4 and CD8 markers, thymocyte maturation was analysed by flow cytometry during mouse development. We observe that the lymphoid defect is detectable starting on embryonic day 15, and is maintained after birth (Figure 5a ). The important decrease in the absolute number of embryonic T cells correlates with a considerable reduction (70-fold at 18.5 dpc to 1000-fold at 3 weeks) of the doublepositive CD4 þ CD8 þ subpopulation. This suggests the failure of the T-cell precursors (CD4À CD8À) to maintain a normal number of DP cells, since the remaining CD4 þ and CD8 þ SP cells correspond to mature cells expressing high level of CD3-e molecule (data not shown). At 3 weeks the DP population progressively disappeared until a complete depletion of mature thymocytes in surviving M33À/À adults (8 weeks). Owing to a variable penetrance of the M33 mutation, the complete loss of DP cells arises in individuals at different stages after weaning. CD4À CD8À double-negative (DN) cells can be further divided into four different subsets using CD44 and CD25 (IL2-R) surface antigens markers (Godfrey and Zlotnik, 1993; Penit et al., 1995) . In order to determine which subpopulation of T-cell precursors was first affected in M33-deficient mice, we used these markers to gate on early events of thymic maturation, at a stage (15 dpc) where most of the thymocytes have an immature DN phenotype in wild-type animals. This analysis reveals that the absolute number of DNIII CD44À CD25 þ subpopulation is particularly affected, with a 150-fold reduction, at this stage in M33-deficient embryos (Figure 5b ). Since the transition from CD44 þ CD25 þ DNII to CD44À CD25 þ DNIII, as well as the generation of DP thymocytes from immature DNIV precursors, is accompanied by a massive cellular proliferation, it is likely that in M33 mutant mice the T-cell precursors are impaired in this function. To go deeply into this expansion defect, the potential of the DN cell population to reconstitute the DP compartment was assessed (Scollay, 1991) . Control and mutant mice were treated with glucocorticoid, known to eliminate the majority of DP but not DN thymocytes (Wyllie, 1980) . We analysed T-cell expansion and maturation after the mice have been injected by hydrocortisone. In mutant and wild-type mice, cortical DP thymocytes were equally sensible to hydrocortisone treatment since they were totally depleted. However, in mutant mice after a 9-days period, the DN precursors was unable to rescue a normal number of thymocytes as well as to give rise to CD4 þ CD8 þ population in a significant amount (Figure 5c ).
Similarly, B-cell expansion was also greatly affected in M33À/À bone marrows (Figure 6 ). The total number of B-lineage cells (B220 þ ) was strongly reduced in 3-weekold M33À/À mice (50% of control) and this defect was amplified with age (66% of control). However, as observed in the thymus, all the maturation stages could be detected but in different proportions. The pre-B II (B220 þ CD43À IgMÀ, fraction D) population appeared to be the most affected in term of cell number, with a 2-3-fold reduction. The pro-B-cell population expressing CD43 and a low level of B220 at the cell surface (fractions A-C) was slightly reduced ( Figure  6a) . However, the B220low CD25À HSA þ late pro-B (fraction B-C) was significantly reduced (five-fold reduction), whereas fraction A (B220low CD25À HSAÀ) was similar in M33À/À and control mice (Figure 6b) . In 8-week-old mutant animals, the B compartment was mainly composed of mature B220hi IgM þ population that are long-lived and recirculating B cells, revealing the inability of precursor cells to renew the B lineage.
Analysis of T (CD3 þ ) and B (B220 þ ) splenocytes showed that, in addition to a strong decrease in total nucleated cell number, the B compartment was more severely affected (up to 60% reduction) than the T During T-cell maturation, the anti-apoptotic BCL-2 protein is expressed in CD4À CD8À DN and in CD4 or CD8 single-positive (SP) cells, but is downregulated in most of the DP that have failed positive selection (Veis et al., 1993) . Enforced Bcl-2 expression has been demonstrated to protect developing and mature T cells from apoptotic stimuli (Maraskovsky et al., 1997) . In addition, it has been shown that overexpression of Bcl-2 in IL7-R-and gC-deficient mice, which present a strong reduction in the number of thymic precursors and a defect of the DN-DP transition, allowed partial rescue of T lymphopoı¨esis Kondo et al., 1997) . Transgenic mice expressing the Bcl-2 gene under the control of the 5 0 Igh enhancer (Em) promote an enhanced survival capacity of the CD4 þ CD8 þ T cells. To test if the CD4 þ CD8 þ immature thymocytes from M33À/À mutants presented an enhanced sensibility to Bcl-2-mediated apoptosis, M33 knockout mice were crossed to EmSV-Bcl-2-25 transgenic mice. Compared analysis of thymic maturation in control, EmSVBcl-2-25, M33À/À, and compound genotype mice revealed that overexpression of Bcl-2 in immature T cells was not able to significantly increase the number of DP cells detected in the absence of M33 (Figure 5d ). This result indicates that the altered phenotype observed in M33À/À thymus is not due to a massive apoptotic event dependent on the BCL-2 product.
Together, these results highlighted the inability of lymphoid cells to expand in the absence of M33 from fetal life to adulthood. This expansion failure could be due to a proliferative defect of precursor cells at different stages of lymphoid development, in fetal liver as well as in the thymus and bone marrow. Alternatively, but not exclusively, it could be due to a defect in positive selection of pro-T and pro-B cells. However, Figure 5 Early developmental defects during thymic ontogeny in M33À/À mice. T-cell maturation was examined by flow cytometric analysis using fluorochrome-conjugated antibodies directed to CD25, CD44, CD8 and CD4. Absolute numbers are given for total thymocytes (above boxes), as well as for subset populations. (a) Expression of the CD4 and CD8 surface molecules was analysed during mouse development at different stages: 18.5 dpc, 3 and 8 weeks after birth. The differentiation profiles of two different 3-weekold animals are presented to underline the variable penetrance of the M33À/À phenotype resulting in strong reduction or complete depletion of CD4 þ CD8 þ population. (b) Thymocytes were recovered from 15 dpc embryos and stained for CD44 and CD25 antigens. (c) The reconstitution of the CD4 þ CD8 þ DP cellular compartment from T-cell progenitors was examined 9 days after hydrocortisone treatment of M33À/À or control mice. (d) Analysis of thymic maturation in M33À/À with enforced expression of BCL-2. Absolute numbers of CD4À CD8À DN (open bar), CD4 þ CD8 þ DP (dotted bar), CD4 þ (hatched bar) and CD8 þ (black bar) SP cell populations have been evaluated by flow cytometry using antibodies to CD4 and CD8. Analysis was performed from 3-week-old animals of different genotypes as indicated. EmSV-Bcl-2-25 transgenic mice overexpress human BCL-2 in the developing thymocytes. Data were shown as means7s.d.
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N Coré et al in adult M33À/À animals, we observed a complete depletion of lymphoid cells as a consequence of progressive exhaustion of precursors with age. In addition, enforced BCL2 expression, which has been described to be able to restore positive selection Kondo et al., 1997) , had no effect on the survival of M33À/À DP thymocytes. These observations seem rather in favor of an intrinsic proliferative defect than a lack of selection. Given the recent observation that the enx1/ezh2 gene is an E2F-pRb target gene, and the relevance of ezh2 for lymphoid proliferation, we have checked for ezh2 expression in mutant thymocytes and seen that the level of expression was not altered in M33À/À adult mice (data not shown).
Since in MEFs we showed that the Ink4a/Arf locus was under the control of M33, we asked if, similarly, the lymphoid cell expansion defect could be associated to deregulation of this locus. In B and T lymphocytes, semiquantitative RT-PCR experiments revealed an important transcriptional upregulation of p16INK4a in M33À/À thymocytes and splenocytes (Figure 2c ). However, whereas in MEFs we detected small differences in the accumulation of p19ARF product, we observed a strong overexpression of its transcript in mutant lymphoid cells. The deregulation of these cyclindependent kinase inhibitors strongly suggests that, in the absence of M33, lymphoid cells fail to expand as a consequence of a proliferative defect.
These results demonstrate a role of M33 in regulating cellular proliferation and senescence in MEFs through the INK4a cyclin-dependent kinase inhibitors, probably by repressing these genes at the transcriptional level. In addition, we present many evidences suggesting that M33 plays a similar role during lymphoid development. These results also suggest that M33 may exert its repressive function on p16INK4 and/or p19ARF expression in a tissue-specific manner.
Discussion
Pc-G family proteins act as transcriptional repressors of
Hox genes and they collaborate with TrxG proteins, which activate Hox gene expression, to impose the patterns of Hox expression during development. In addition, Pc-G proteins have been implicated in regulating cell cycle progression essentially described Disruption of E2F signaling N Coré et al during hematopoı¨esis (Jacobs and van Lohuizen, 2002) and in embryonic fibroblasts (Jacobs et al., 1999a) . In the present study, we showed that M33 controls the cell cycle progression of embryonic fibroblasts. M33-deficient MEFs enter a slower rate of division, leading cells to go into premature senescence, accumulating the cell cycle inhibitor protein p16INK4a. We demonstrated that the p16INK4a-induced proliferative defect was bypassed by disrupting the E2F signaling pathway, linking M33 to the cell cycle.
The Ink4a/Arf tumor suppressor locus was identified as a critical downstream target of bmi-1 (Jacobs et al., 1999b) . This locus encodes for both p16INK4a, which prevents inactivation of the tumor suppressor pRB, and p19ARF, which acts to avoid the degradation and inactivation of the tumor suppressor p53 (Sherr, 2001 ). Activation of p16INK4a and p19ARF restrains cell proliferation and occurs when cells reach their maximum number of cell divisions. Absence of bmi-1 causes upregulation of p16INK4a and p19ARF expression, leading to impaired proliferation and premature entry of bmi-1-null MEFs into senescence as well as severe proliferation defects in the hematopoietic system (Jacobs et al., 1999a). Absence of M33 causes a preferential deregulation of the p16INK4a product in MEFs, whereas both p16INK4a and p19ARF are upregulated in M33À/À in lymphoid organs. Mice, specifically lacking p16INK4a, develop normally, except for a thymic hyperplasia which was most marked in the double-positive compartment (Krimpenfort et al., 2001 ). In addition, T cells present enhanced mitogenic response, consistent with the established role of p16INK4a in restricting lymphocyte proliferation. However, p16INK4a-null MEFs present normal growth characteristics and are still susceptible to Ras-induced senescence. On the contrary, p19ARF-null MEFs express an appropriate level of p16INK4a and do not undergo senescence (Kamijo et al., 1997) . Whereas loss of function of p16INK4a does not interfere with cell cycle progression and senescence in rodent MEFs, gainof-function experiments have showed that forced expression of p16INK4a in human fibroblasts induces senescence as cells fail to proliferate and are positive for SA-b-gal (Dimri et al., 1995) . Thus, an abnormal high level of this molecule is sufficient to trigger a senescent phenotype, independently of p19ARF activity. Therefore, abnormal accumulation of p16INK4a per se could be sufficient to cause the M33 senescent phenotype in MEFs. It will be then important to breed M33 mutant mice to p16INK4a-deficient mice in order to evaluate which of the INKa/ARF product contributes to the proliferation defects in M33 mutants.
It is well established that growth arrest induced by the p16INK4a signaling pathway is mediated by the repressive function of the E2F family of transcriptional factors (Lukas et al., 1996) . More recently, it has been shown that the antiproliferative p19ARF signaling as well converges to E2F-mediated repression of critical target genes (Rowland et al., 2002) . The repressive function of E2F depends on its interaction with the pRB protein to form a repressor complex that directly binds to the DNA of downstream targets. A mutant form of E2F-1, namely E2F-DB, lacks the pRB-interacting domain as well as the transactivation domain, but is still capable of binding DNA and displacing endogenous E2F-1/pRB complexes from their binding sites. It has been demonstrated that E2F-DB mutant protein prevents P16INK4a-mediated growth arrest and allows cells to proliferate at a normal rate even with a high level of the P16INK4a inhibitor (Zhang et al., 1999) . In addition, recent data show that E2F-DB can rescue cell cycle arrest induced by ectopic p19ARF expression in MEFs (Rowland et al., 2002) . Moreover, relief of transcriptional repression by E2F rendered MEFs resistant to senescence induced by either p19ARF and p53. In our study, we showed that M33-deficient MEFs were able to proliferate properly when they express E2F-DB, demonstrating that E2F-DB totally rescues the M33 antiproliferative phenotype in MEFs. Therefore, disruption of the E2F signaling is sufficient to bypass the p16INK4a and p19ARF pathways, suggesting that the proliferation block in M33 mutant cells is specifically due to the deregulated expression of the Ink4a/Arf locus.
During T-cell ontogeny, b selection triggers expansion of the immature CD4À CD8À CD44À CD25 þ DNIII population. Later on, double negative DNIV CD4À CD8À cells accomplish an additional step of massive proliferation as they go through maturation to the DP stage. From this study, it can be concluded that M33-deficient thymocytes have an impaired capability of expanding at both these stages. This result is emphasized by experiments using glucocorticoid treatment showing that the CD4À CD8À precursor cells fail to reconstitute a normal number of DP cells in the thymus of mutant mice. Similarly, in the bone marrow, the pre-B II (B220 þ CD43À IgMÀ) population, which is generated from an extensive proliferative event, is strongly affected, indicating that developing B cells are also impaired in their expansion process. It is likely that, in the absence of M33, lymphoid cells fail to expand as a consequence of a proliferative defect, rather than a problem of selection. Inactivation of the M33 function did not block lymphocyte differentiation since all mature populations are present in mutant lymphoid organs but in reduced amount. In M33À/À thymus and bone marrow, we observed a progressive exhaustion of the precursor cells with age, which denote a potential defect in cellular proliferation. In addition, enforced expression of BCL-2 in the thymus does not rescue the lymphoid compartment of M33À/À mice, indicating that the abnormal cellularity is not due to a major increase in the apoptotic pathway linked to an abnormal selection process. Alternatively, we cannot exclude that the decrease of lymphoid populations is caused by the loss of early hematopoietic precursors.
BMI-1 and M33 are components of a multimeric complex that is thought to regulate transcriptional activity of various target genes (Alkema et al., 1997a; Bel et al., 1998) . Cooperation and synergism between these two gene functions have already been described in a previous work related to the transcriptional regulation Disruption of E2F signaling N Coré et al of Hox genes during development (Bel et al., 1998) . Our present study reveals that M33 suppresses transcriptional expression of the Ink4a/Arf locus that encodes the tumor suppressors p16INK4a and p19ARF in lymphoid cells. Consequently, the functional synergism between M33 and bmi-1 could be effective in regulating cell cycle both in lymphoid precursor cells and embryonic fibroblasts. It is likely that Polycomb repressive complex 1 (PRC1) multiprotein complex is required for the regulation of the Ink4a locus in thymocytes and MEFs; removing the M33 protein from this complex probably induces a destabilization of PRC1 leading to misexpression of target genes. Recently, it has been established that bmi-1 and rae28, another Pc-G component, are essential for maintenance of self-renewing adult HSCs (Ohta et al., 2002; Park et al., 2003) . Moreover, expression data reveal that p16INK4a and p19ARF expression is altered in bone marrow cells from bmi-1 mutant. Owing to the similarity between M33 and bmi-1 in cell cycle control in MEFs and on Ink4a/Arf expression, it will be then important to assess M33 function in HSC self-renewal potential. A role of M33 in this process may well account for the expansion failure of lymphoid populations in M33-deficient animals.
Materials and methods
Mice
The generation of the M33-deficient mouse was previously described (Core´et al., 1997) . All experiments were performed with wild-type and M33 mutant mice that were bred on the BALB/c background. EmSV-Bcl-2-25 transgenic mice expressing the human Bcl-2 transgene in T-lineage cells (Strasser et al., 1991) are of C57BL/6 background. M33/Bcl-2 mice were generated by intercrossing the respective parental strains, and were bred on the hybrid BALB/c Â C57BL/6 background.
Glucocorticoid administration
Mice were injected i.p. with 100 mg/g hydrocortisone 2.5% (Roussel). At the indicated time, mice were killed and cell suspension was prepared from thymus lobes for FACS analysis.
Plasmids A 1.2 kb fragment containing the mutant form of E2F-1 (E2F-DB) was amplified by high-fidelity platinum Taq Polymerase (Invitrogen) from the pCMVE2F1 (1-374) plasmid (Helin and Harlow, 1994) using primers: sense -5 0 -AGAATTCCTC GACGGATCCGCCA-3 0 and antisense -5 0 -GTGAATTCC TAGACGGATCCAGC-3 0 . The PCR product was subcloned first into pGEMT-easy vector (Promega), then excised by EcoRI digestion and subsequently cloned into the EcoRI site of LZRS-ires-GFP retroviral vector to generate pLZRS-E2DB-ires-GFP plasmid.
Cell culture conditions
Embryonic fibroblasts (MEFs) were prepared from 12.5 dpc embryos as described (Core´et al., 1997) . For retroviral infection, 2 Â 10 6 packaging cells (Plat-E) were transfected with 3 mg of retroviral plasmid DNA using Lipofectamine plus reagent (Invitrogen) to produce the viral supernatant. Transfection efficiency was checked by GFP expression under the microscope. At 4 days after transfection, subconfluent passage 2 MEF cultures were infected by the retroviral supernatant containing 4 mg/ml polybrene for 24 h at 371C. GFP-positive population was sorted out by FACS 72 h post infection and 3 Â 10 4 cells were seeded per well into a six-well plate. Cells in triplicate wells were then counted every 3 days by trypan blue exclusion, and sustained GFP expression was checked by FACS. The same experimental protocol has been realized on MEFs generated from three different embryos of each genotype and from two different litters.
Senescence-associated b-gal staining was performed as previously described (Serrano et al., 1997) . For cell cycle analysis, MEFs were treated with 10 mM BrdU (Sigma) for 4 h, then harvested, rinsed in PBS, and fixed dropwise at 41C with pre-chilled 70% ethanol. After overnight fixation, cells were resuspended in 2 N HCl for 30 min, then incubated for 5 min with 0.1 M Borax pH8.5 and washed twice in PBS. Cells were stained for 30 min with 20 ml FITC-conjugated anti-BrdU antibody (clone 3D4, Pharmingen), treated with 1 mg/ml Rnase-A (Amersham Pharmacia) and then incubated for 30 min with 25 mg/ml propidium iodide (Sigma) before flow cytometric analysis.
Flow cytometry
Flow cytometric analysis was performed as described in Coreé t al. (1997) . The number of nucleated cells was counted by trypan blue exclusion. The antibodies are from Pharmingen and Caltag Laboratories.
Western blot
Immunoblotting was performed according to standard methods using polyclonal antisera: anti-p19ARF (ab80, Abcam), anti-p16INK4a (M-156, Santa Cruz Biotechnology), anti-actin (20-33, Sigma), and monoclonal anti-E2F1 (KH20, Sigma). Immunoblots were revealed by enhanced chemiluminescence (Amersham Pharmacia).
Expression analysis
Total RNA from thymocytes and splenocytes was extracted using Trizol reagent (Invitrogen). Semiquantitative reverse transcription-PCR was performed with SuperScriptII and oligo-dT according to the manufacturer's protocol (Invitrogen). PCR reaction was carried out on serial dilutions of firststrand cDNA using 35 cycles of denaturation (941C, 45 s), annealing (621C, 30 s), elongation (721C, 2 min) with the following primers: specific sense primers for p16INK4 5 0 -CACGACTGGGCGATTGGGC-3 0 (exon1ae) and p19ARF 5 0 -GGTCGCAGGTTCTTGGTCAC (exon1b) in combination with a shared antisense primer in exon2 5 0 -AGGCATCGC CACATCCAGC-3 0 . Primers specific for b-actin were used as an internal control: sense -5 0 -GTGGGCCGCTCTAGGCAC CAA-3 0 , antisense -5 0 -CTCTTTGATGTCACGCACGATT TC-3 0 . Products were resolved on 1.5% agarose gel.
